Thrilled to anounce that one of our Portfolio Companies (Lindy Biosciences, Inc.) has landed its first Global Licensing Deal. This is a major milestone for the company allowing it to take its innovative MicroGlassification technology and create subcutaneious injections for therapeutic that would otherwise need to be administered through an IV. This significantly changes the patient experience allowing them to complete the process in under a minute rather than having to sit at an infusion center.
We are thrilled to announce a major milestone: Lindy Biosciences has entered into a global licensing and collaboration agreement with Novartis for our cutting-edge drug formulation and delivery platform. This deal marks a significant step forward in our mission to return patients to control and independence. 🔹 Solving for the limitations in biologics delivery systems: Novartis gains multi-target exclusive global rights to our microglassification suspension technology, designed to deliver high-dose biologics by convenient subcutaneous injections. 🔹 A new pace on patient care: This collaboration is set to enhance self-administration of high-concentration treatments, potentially improving patient outcomes and compliance.  Learn More: https://lnkd.in/eKSv_sCs  #Biotech #DrugDelivery #Innovation #Healthcare #Biologics #Pharma #News